Facilities also include cell culture suites, quality control labs and technical labs
Bristol-Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, worth a billion dollars in investment, was officially opened by Giovanni Caforio, the company’s chief executive, who arrived from New York, and his Pádraig Keane, the site’s general manager.
The facility, which spans over 125 acres, received U.S. Food and Drug Administration (FDA) approval in 2019 and European Medicines Agency (EMA) site approval the following year and is now in commercial production.
With more than 450 employees on campus, Cruiserath will provide the manufacturing capacity needed to meet growing demand for existing biologics and the anticipated requirements for products currently in Bristol-Myers Squibb’s pipeline. I have it.
It also includes a cell culture suite, quality control lab, technical lab and cryogenic logistics facility. All ventures support ongoing commercial testing, development and manufacturing.
Padraig Keane explains: The manufacturing of biologics is a highly complex and delicate process that is truly unique, from manufacturing to packaging, storage and transportation to reach the patient. “
“This requires commitment from each employee across all departments and collaboration across our network. Our employees discover and develop innovative medicines that help patients overcome serious illnesses. ,” he added.
Karin Shanahan, who leads the company’s global manufacturing network, commented: Combined with the extensive knowledge and expertise of our employees, this multi-product site will further enhance our operations as we strive to bring more medicines to more patients, faster. “
Bristol-Myers Squibb became one of Ireland’s first pharmaceutical companies when it opened a pharmaceutical raw material plant in County Dublin in 1964.
